COVID-19 vaccine release time can be judged in phase III

Vaccine prices expected to range from $8 to $50

Mook Hyun-sang, Head of the KDDF

With the time to release the COVID-19 vaccine, a domestic expert said that it is not yet in the stage of discussion.

 

Mook Hyun-sang, the head of Korea Drug Development Fund (KDDF) announced the results at the future open discussion with the theme of 'COVID-19 vaccine, global development trend and securing strategy' co-sponsored by the MOHW and the KHIDI.

 

He said, "In the WHO announcement as of July 28, there are five COVID-19 vaccines in progress in phase III, and there are opinions among foreign experts that if the phase I/II drugs are confirmed, the vaccine can be released within this year, and safety must be carefully considered."

In relation to the release of the vaccine, the director of the NIAID, Fauci, said, "If only phase I and II drugs are confirmed, a licensed vaccine can be released within this year." Ken Frazier, the president and CEO of MSD, who developed the Gardasil said, "we have developed most of the new vaccines in the last 25 years, but it's not a simple thing to prove safety." He said that Dr.

 

Fauci is hopeful, and President Frazier is in a position to go safely.

 

No one can say that the vaccine will be released within six months, a year or two.

 

The conclusion emphasized that it is possible to discuss the timing of vaccine release only after confirming the data of the inoculated patients after 3 and 6 months in phase III.

 

In addition, regarding the price of vaccines, AstraZeneca predicts that supply contracts will be made at around $8 per person and Moderna at around $50 per person.

 

He was concerned that vaccine prices range from $8 to $50 depending on how they are negotiated, If the Korean population is 1 billion, it will receive a good price, but negotiations are ambiguous in the situation of 50 million.

 

He judged that it is reasonable for the government's strategy to make efforts to develop and secure the COVID-19 vaccine through a two-track strategy, such as the introduction of the vaccine itself and the introduction of overseas vaccines.

 

He said, "Since we haven't made efforts on the vaccine source technology, it is not easy to enter into global joint research and development.

 

Therefore, the government is pursuing a strategy to introduce the vaccine itself and introduce it into overseas development.

 

Japan has also signed a CMO contract with AstraZeneca and Daichi Sankyo, and the MOHW is also making efforts to sign a CMO contract with SK Biosciences."